Copyright
©The Author(s) 2015.
World J Virology. Nov 12, 2015; 4(4): 343-355
Published online Nov 12, 2015. doi: 10.5501/wjv.v4.i4.343
Published online Nov 12, 2015. doi: 10.5501/wjv.v4.i4.343
Table 3 Treatment of chronic hepatitis E virus with ribavirin regimen
Ref. | Type of study | Patient profile | Ribavirin regimen | Result | Adverse effects |
Kamar et al[99] | Prospective case series | 6 kidney transplant recipients, HEV RNA (+) for median of 36.5 mo | 600-800 mg/d for 3 mo adapted to GFR, Hgb | SVR in 4/6 patients; relapse in 2/6; AST, ALT normalized all | Anemia led to blood transfusion and RBV dose reduction in 2/6 patients |
Mallet et al[105] | Case report | A kidney and pancreas transplanted man, a women with idiopathic CD4+ T lymphocytopenia | 12 mg/kg daily for 12 wk | Both cleared HEV after 4 wk of treatment and remained undetectable, LFT normalized | Anemia in 1st patient led to Ribavirin dose reduction to 200 mg/d |
Pischke et al[96] | Prospective case series | Organ transplant recipients 11 subjects | 600-1000 mg/d for 5 mo, dose reduction according to Hgb or anemia | 9/11 showed SVR | Anemia, the mean Hgb decline was 3.4 g/dL (range 0-7.9 g/dL) |
Neukam et al[106] | Case report | 2 HIV (+) male with liver cirrhosis with severe immunosuppression | Oral ribavirin 1200 mg/d (case 1) 1000 mg/d (case 2) for 24 wk | LFT normalized-Liver stiffness improved HEV RNA was detected after the end of treatment in both patients | - |
Giordani et al[107] | Case report | 60-year-old man with lymphocytic leukemia | 1000 mg/d in 2 doses (400 and 600 mg), for 3 mo | HEV cleared and sustained over 6 mo after therapy | Mild anemia (Hgb 10.5 mg/dL) |
Kamar et al[100] | Retrospective, multicentre case series | 37 kidney, 10 liver, 5 heart, 5 kidneys and pancreas, and 2 lung transplant recipients with chronic HEV | Median dose of 600 mg/d (range 29-1200), for a median of 3 mo (range 1-18 mo) | At the end of the therapy, 95% cleared HEV, 18% recurred after cessation of therapy is stopped, 78% showed SVR | Anemia required dose reduction (29%); use of erythropoietin (54%); required blood transfusion (12%) |
- Citation: Lee GY, Poovorawan K, Intharasongkroh D, Sa-nguanmoo P, Vongpunsawad S, Chirathaworn C, Poovorawan Y. Hepatitis E virus infection: Epidemiology and treatment implications. World J Virology 2015; 4(4): 343-355
- URL: https://www.wjgnet.com/2220-3249/full/v4/i4/343.htm
- DOI: https://dx.doi.org/10.5501/wjv.v4.i4.343